



Natural Products and Bio-Nanomaterials: Novel Strategies to Overcome Antibiotic Resistance

Guest Editors:

Dr. Renata Katsuko Takayama Kobayashi

Department of Microbiology,
Universidade Estadual de
Londrina, Londrina, Brazil

Dr. Gerson Nakazato

Department of Microbiology,
Universidade Estadual de
Londrina, Londrina, Brazil

Dr. Sara Scandorieiro

Department of Microbiology,
Universidade Estadual de
Londrina, Londrina, Brazil

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editors

Natural products are a trend in biomedical applications as antimicrobials due to their low toxicity and environmental safety. Many different plants have been used as pharmaceuticals with benefits and advantages in infection control. However, this use alone presents some difficulties (cost, efficacy, seasonality, etc.) suggesting increments in their compounds.

Nanotechnology or Nanoscience is the study and application of small particles (between 1 and 100 nm) to produce new structures, material, and devices. This size and charge allow optimizing some physicochemical properties, as well as biological activities. Some nanomaterials with antimicrobial effects have been applied in the field of medicine with satisfactory results. These materials can adopt interesting strategies such as nanoencapsulation, compounds delivery, magnetic targeting and synergic associations.

In this way, our Special Issue will receive articles focusing on the antimicrobial activity using natural products (from marine, plants, microorganisms, etc.) and bionanomaterials for prevention or therapy against pathogens, including MDRs. Authors can send original research or review approaching this theme.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)